Pharmacological inhibition of NOS activates ASK1/JNK pathway augmenting docetaxel-mediated apoptosis in triple negative breast cancer.

CONCLUSION: iNOS is a critical target for docetaxel resistance in TNBC. Pharmacological inhibition of NOS enhanced chemotherapy response in TNBC PDX models. Combination therapy may improve prognosis and prevent relapse in TNBC patients who have failed conventional chemotherapy. PMID: 29301832 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29301832?dopt=Abstract

Source: Clinical Cancer Research - January 4, 2018 Category: Cancer & Oncology Authors: Dávila-González D, Choi DS, Rosato RR, Granados-Principal S, Kuhn JG, Li WF, Qian W, Chen W, Kozielski AJ, Wong HH, Dave B, Chang JC Tags: Clin Cancer Res Source Type: research